Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Servier
Eli Lilly and Company
Instituto do Cancer do Estado de São Paulo
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Pfizer
Pfizer
Stanford University
Jonsson Comprehensive Cancer Center
xCures
University of Nebraska
Adela, Inc
Eli Lilly and Company
Degron Therapeutics Co.
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
The University of Texas Health Science Center at San Antonio
M.D. Anderson Cancer Center
Ikena Oncology
Washington University School of Medicine
Jonsson Comprehensive Cancer Center
Azienda Ospedaliera di Padova
Apollomics Inc.
Columbia University